One particular type of BRAF mutation, called BRAF V600E, is present in around 5% to 10% of patients with metastatic colorectal cancer. Historically, metastatic colorectal cancer driven by a BRAF ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

as well as an increase in overall survival (OS), when used as a first-line treatment for colorectal cancer with BRAF V600E mutations. Both results were "clinically meaningful," according to a ...

Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer ... people diagnosed with bowel cancer who have a BRAF V600E mutation are currently extremely ...

such as melanoma or colorectal. There are several types of BRAF mutation that can occur, but the most common type is V600E. Adenocarcinoma refers to the location where lung cancer starts.

Braftovi (encorafenib), for treating patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targets BRAF V600E.

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

The Braftovi combination regimen received accelerated approval by the FDA in December 2024 for treatment-naive patients with BRAF V600E-mutant mCRC based on a clinically meaningful and ...

In combination with trametinib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Not for treatment of colorectal cancer ...